Christian Mölleken, Maike Ahrens, Anders Schlosser, Julia Dietz, Martin Eisenacher, Helmut E. Meyer, Wolff Schmiegel, Uffe Holmskov, Christoph Sarrazin, Grith Lykke Sorensen, Barbara Sitek, Thilo Bracht
Clin Mol Hepatol 2019;25(1):42-51. Published online November 19, 2018
Background/Aims An estimated 80 million people worldwide are infected with viremic hepatitis C virus (HCV). Even after eradication of HCV with direct acting antivirals (DAAs), hepatic fibrosis remains a risk factor for hepatocarcinogenesis. Recently, we confirmed the applicability of microfibrillar-associated protein 4 (MFAP4) as a serum biomarker for the assessment of hepatic fibrosis. The aim of the present study was to assess the usefulness of MFAP4 as a biomarker of liver fibrosis after HCV eliminating therapy with DAAs.
Methods MFAP4 was measured using an immunoassay in 50 hepatitis C patients at baseline (BL), the end-of-therapy (EoT), and the 12-week follow-up visit (FU). Changes in MFAP4 from BL to FU and their association with laboratory parameters including alanine aminotransferase (ALT), aspartate aminotransferase (AST), platelets, the AST to platelet ratio index (APRI), fibrosis-4 score (FIB-4), and albumin were analyzed.
Results MFAP4 serum levels were representative of the severity of hepatic fibrosis at BL and correlated well with laboratory parameters, especially APRI (Spearman correlation, R²=0.80). Laboratory parameters decreased significantly from BL to EoT. MFAP4 serum levels were found to decrease from BL and EoT to FU with high statistical significance (Wilcoxon P<0.001 for both).
Conclusions Our findings indicate that viral eradication resulted in reduced MFAP4 serum levels, presumably representing a decrease in hepatic fibrogenesis or fibrosis. Hence, MFAP4 may be a useful tool for risk assessment in hepatitis C patients with advanced fibrosis after eradication of the virus.
Citations
Citations to this article as recorded by
Pathological Changes in Extracellular Matrix Composition Orchestrate the Fibrotic Feedback Loop Through Macrophage Activation in Dupuytren’s Contracture Elizabeth Heinmäe, Kristina Mäemets-Allas, Katre Maasalu, Darja Vastšjonok, Mariliis Klaas International Journal of Molecular Sciences.2025; 26(7): 3146. CrossRef
MFAP4 Deficiency Attenuates Liver Fibrosis by Regulating Hepatic Stellate Cell Fate Through Inhibition of the FAK/PI3K/NFκB Signaling Pathway Linxiang Liu, Bimin Li, Yue Zhang, Yuan Nie, Wang Zhang, Peng Chen, Chenkai Huang, Xuan Zhu Cellular and Molecular Gastroenterology and Hepatology.2025; 19(10): 101548. CrossRef
Role and new insights of microfibrillar‐associated protein 4 in fibrotic diseases Long Zhu, Wenqun Gou, Lijia Ou, Binjie Liu, Manyi Liu, Hui Feng APMIS.2024; 132(2): 55. CrossRef
Standardizing urethral stricture models in rats: a comprehensive study on histomorphologic and molecular approach Osman Ergün, Muhammet Yusuf Tepebaşi, İbrahim Onaran, Sefa Alperen Öztürk, Mücahit Baltik, Pinar Aslan Koşar International Urology and Nephrology.2024; 56(9): 2945. CrossRef
Predictors of liver fibrosis changes assessed by paired liver biopsies in chronic hepatitis C patients treated with direct-acting antivirals Ming-Han Hsieh, Tzu-Yu Kao, Ting-Hui Hsieh, Chun-Chi Kao, Cheng-Yuan Peng, Hsueh-Chou Lai, Hsing-Hung Cheng, Mao-Wang Ho, Chih-Yu Chi, Jung-Ta Kao Journal of Microbiology, Immunology and Infection.2024; 57(6): 840. CrossRef
Matrisome gene-based subclassification of patients with liver fibrosis identifies clinical and molecular heterogeneities Wei Chen, Yameng Sun, Shuyan Chen, Xiaodong Ge, Wen Zhang, Ning Zhang, Xiaoning Wu, Zhuolun Song, Hui Han, Romain Desert, Xuzhen Yan, Aiting Yang, Sukanta Das, Dipti Athavale, Natalia Nieto, Hong You Hepatology.2023; 78(4): 1118. CrossRef
Microfibrillar-associated protein 4 in health and disease Reine Kanaan, Myrna Medlej-Hashim, Rania Jounblat, Bartosz Pilecki, Grith L. Sorensen Matrix Biology.2022; 111: 1. CrossRef
Molecular structure and function of microfibrillar‐associated proteins in skeletal and metabolic disorders and cancers Sipin Zhu, Lin Ye, Samuel Bennett, Huazi Xu, Dengwei He, Jiake Xu Journal of Cellular Physiology.2021; 236(1): 41. CrossRef
Molecular Crosstalk between the Hepatitis C Virus and the Extracellular Matrix in Liver Fibrogenesis and Early Carcinogenesis Emma Reungoat, Boyan Grigorov, Fabien Zoulim, Eve-Isabelle Pécheur Cancers.2021; 13(9): 2270. CrossRef
Circadian, Week-to-Week, and Physical Exercise-Induced Variation of Serum Microfibrillar-Associated Protein 4 Susanne Gjørup Sækmose, René Holst, Tine Lottenburger, Henriette Ytting, Hans Jørgen Nielsen, Peter Junker, Anders Schlosser, Grith Lykke Sorensen Biomarker Insights.2021;[Epub] CrossRef
Pathological investigations and correlation research of microfibrillar-associated protein 4 and tropoelastin in oral submucous fibrosis Binjie Liu, Wenqun Gou, Hui Feng BMC Oral Health.2021;[Epub] CrossRef
The fibrotic response of primary liver spheroids recapitulates in vivo hepatic stellate cell activation Inge Mannaerts, Nathalie Eysackers, Elise Anne van Os, Stefaan Verhulst, Tiffany Roosens, Ayla Smout, Andreas Hierlemann, Olivier Frey, Sofia Batista Leite, Leo A. van Grunsven Biomaterials.2020; 261: 120335. CrossRef
Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals Hye Won Lee, Dai Hoon Han, Hye Jung Shin, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Cancers.2020; 12(11): 3414. CrossRef
Real-world single-center experience with direct-acting antivirals for improvement of the liver fibrosis after chronic hepatitis C treatment Sun Hee Lee, Hyun Phil Shin, Joung Il Lee Antiviral Chemistry and Chemotherapy.2020; 28: 204020662097483. CrossRef
Relationship between Microfibrillar-Associated Protein 4 Levels and Subclinical Myocardial Damage in Chronic Kidney Disease Sonat Pınar Kara, Gülsüm Özkan, Demet Özkaramanlı Gür, Gaye Kübra Emeksiz, Ahsen Yılmaz, Nergiz Bayrakçı, Savaş Güzel Cardiorenal Medicine.2020; 10(4): 257. CrossRef
Biomarker microfibril-associated glycoprotein 4 for non-invasive diagnosis and therapeutic evaluation of hepatic fibrosis in patients with hepatitis C Young Woo Eom, Soon Koo Baik Clinical and Molecular Hepatology.2019; 25(1): 37. CrossRef
First
Prev
